ArticleEukaryotic cell2003
Formation and remodeling of inositolphosphoceramide during differentiation of Trypanosoma cruzi from trypomastigote to amastigote.
Article in Eukaryotic cell, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Overproduction and Characterization of Recombinant SolubleEngineering in life sciences · 2025Article
- Phospholipases A and Lysophospholipases in protozoan parasites.Microbial cell (Graz, Austria) · 2023Review
- Quantitative Structure-Activity Relationships for Structurally Diverse Chemotypes Having Anti-International journal of molecular sciences · 2019Article
- The antifungal Aureobasidin A and an analogue are active against the protozoan parasite Toxoplasma gondii but do not inhibit sphingolipid biosynthesis.Parasitology · 2018Article
- Transcriptome Remodeling in Trypanosoma cruzi and Human Cells during Intracellular Infection.PLoS pathogens · 2016Article
- Sialic Acid Glycobiology Unveils Trypanosoma cruzi Trypomastigote Membrane Physiology.PLoS pathogens · 2016Article
- Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis.Antimicrobial agents and chemotherapy · 2015Article
- Evasion of the Immune Response by Trypanosoma cruzi during Acute Infection.Frontiers in immunology · 2015Review
- Sphingolipid and ceramide homeostasis: potential therapeutic targets.Biochemistry research international · 2012Article
- Phospholipases a in trypanosomatids.Enzyme research · 2011Article
- The Sphingolipid Biosynthetic Pathway Is a Potential Target for Chemotherapy against Chagas Disease.Enzyme research · 2011Article
- Phospholipid and sphingolipid metabolism in Leishmania.Molecular and biochemical parasitology · 2010Review
- Sphingolipids in parasitic protozoa.Advances in experimental medicine and biology · 2010Review
- Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.Antimicrobial agents and chemotherapy · 2009Article
- Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs.Interdisciplinary perspectives on infectious diseases · 2009Article
- In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects.Antimicrobial agents and chemotherapy · 2008Article
- Phospholipid and glycolipid composition of acidocalcisomes of Trypanosoma cruzi.Molecular and biochemical parasitology · 2008Article
- De novo sphingolipid synthesis is essential for viability, but not for transport of glycosylphosphatidylinositol-anchored proteins, in African trypanosomes.Eukaryotic cell · 2007Article
- The protozoan inositol phosphorylceramide synthase: a novel drug target that defines a new class of sphingolipid synthase.The Journal of biological chemistry · 2006Article
- Inhibitory effect of aureobasidin A on Toxoplasma gondii.Antimicrobial agents and chemotherapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Differentiation of Trypanosoma cruzi trypomastigotes to amastigotes inside myoblasts or in vitro, at low extracellular pH, in the presence of [(3)H]palmitic acid or [(3)H]inositol revealed differential labeling of inositolphosphoceramide and phosphatidylinositol, suggesting that a remodeling process takes place in both lipids. Using (3)H-labeled inositolphosphoceramide and phosphatidylinositol as substrates, we demonstrated the association of at least five enzymatic activities with the membranes of amastigotes and trypomastigotes. These included phospholipase A(1), phospholipase A(2), inositolphosphoceramide-fatty acid hydrolase, acyltransferase, and a phospholipase C releasing either ceramide or a glycerolipid from the inositolphospholipids. These enzymes may be acting in remodeling reactions leading to the anchor of mature glycoproteins or glycoinositolphospholipids and helping in the transformation of the plasma membrane, a necessary step in the differentiation of slender trypomastigotes to round amastigotes. Synthesis of inositolphosphoceramide and particularly of glycoinositolphospholipids was inhibited by aureobasidin A, a known inhibitor of fungal inositolphosphoceramide synthases. The antibiotic impaired the differentiation of trypomastigotes at acidic pH, as indicated by an increased appearance of intermediate forms and a decreased expression of the Ssp4 glycoprotein, a characteristic marker of amastigote forms. Aureobasidin A was also toxic to differentiating trypomastigotes at acidic pH but not to trypomastigotes maintained at neutral pH. Our data suggest that inositolphosphoceramide is implicated in T. cruzi differentiation and that its metabolism could provide important targets for the development of antiparasitic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.